GLP-1 drugs like Ozempic and Wegovy have revolutionized the treatment of diabetes and obesity, but their potential effect on cancer prevention remains a mystery. At the latest meeting of the American Association for Cancer Research, experts updated the data without reaching a definitive conclusion. While some studies point to a reduction in tumors in patients with obesity, others find no significant relationship.
Mechanisms under study: inflammation and cellular receptors 🔬
The main hypothesis suggests that these drugs act on GLP-1 receptors present in the pancreas and digestive system, reducing chronic inflammation associated with obesity, a known risk factor for several cancers. Additionally, researchers are investigating whether the drug-induced weight loss generates metabolic changes that hinder tumor growth. However, current clinical trials have not been able to isolate whether the benefit comes from the drug or simply from the reduction of body fat.
Spoiler: losing weight doesn't cure everything (but it helps a lot) 😅
Science is advancing, but it seems that GLP-1 is not the magic pill some hoped for. While researchers debate, patients wonder if injecting Ozempic will save them a visit to the oncologist. For now, the answer is a resounding it depends. In other words, the same as with broccoli or exercise: it's good to have it, but don't expect it to make you immortal. At least, the scale will give you some good news.